Skip to main content
. 2016 Aug 24;15(6):1051–1062. doi: 10.1111/acel.12509

Figure 5.

Figure 5

The APL‐1‐induced longevity requires DAF‐16 and DAF‐12. (a) The longevity of transgenic ynIs105 [Psnb‐1::APL‐1EXT] animals was suppressed by a null mutation in daf‐16, which encodes a FOXO transcription factor. (b) The longevity of transgenic ynIs105 [Psnb‐1::APL‐1EXT] animals was suppressed by a mutation in daf‐12, which encodes a vitamin D‐like nuclear hormone receptor (VDR). (c) The longevity of transgenic ynIs105 [Psnb‐1::APL‐1EXT] animals was additive to the longevity of animals with reduced germ stem cell numbers (glp‐1(e2141)). (d) The longevity of transgenic ynIs12 [Psnb‐1::APL‐1] animals was additive to the longevity of animals with reduced Insulin/IGF‐1 signaling (daf‐2(e1370)). (e–f) mRNA levels of canonical DAF‐16 target genes (sod‐3 and gst‐4) under reduced insulin/IGF‐1 conditions are not altered in animals that overexpress APL‐1. Three independent trials of N > 1000 of mixed‐stage animals per trial were analyzed. Data are represented as mean ± SEM P‐value ***<0.0001 relative to wild‐type (N2) was determined by one‐sample t‐test, two‐tailed, hypothetical mean of 1. For (a–d) P‐value was determined by log rank. Statistics and additional lifespan data are in Tables S2 and S3.